Connect with us

News Wire

BSV Launches PCOS Awareness Drive

MUMBAI, India, Oct. 6, 2021 /PRNewswire/ — BSV, during the PCOS awareness month, has launched an awareness via its microsite Start Your Joy talking about various aspects of PCOS. Leading industry experts also join the awareness and shared their views and experience on Understanding PCOS and infertility.

During this PCOS awareness month, India’s leading IVF experts, supported by BSV, talk about this growing condition and how it affects infertility.

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that causes ovaries to get enlarged and small cysts develop on the outer edges. The cause or causes of PCOS might be a combination of environmental, lifestyle or genetic factors. BSV got experts on board to help understand this better.

Understanding PCOS

PCOS is a common condition associated with an imbalance in female sexual hormones, which may lead to many symptoms like irregular menstrual periods, excessive hair on the face, etc. “A diagnosis of PCOS is almost always associated with an assumption that getting pregnant will be a challenge. PCOS is one of the main causes of infertility,” Dr Vandana Hegde, Clinical Director – Hegde Fertility, Hyderabad, says. “In fact, 50 per cent of women who have difficulty in conceiving are found to have PCOS.” The signs and symptoms of PCOS usually show up in late adolescence or early adulthood, she points out. They can include:

  • Excess hair growth on the face or other places which is usually typical to males.
  • Thinning hair on the scalp.
  • Oily skin or severe acne.
  • Skin tags on the neck or armpits.
  • Patches of thick, darkened skin, particularly on the neck, groin, or underneath the breasts.
  • Weight gain or difficulty losing weight.
  • High levels of insulin in blood.

PCOS And Infertility

For infertility caused by PCOS, treatment involves correcting any ovulation issues and tackling metabolic problems, such as insulin resistance. “There are treatments to help ovulate and conceive,” Dr Richa Jagtap, Clinical Director, NOVA IVF Fertility, Chembur, Mumbai adds. “It can also be used to help regulate menstrual cycles and provide protection from endometriosis in women with irregular periods associated with PCOS.” Maintaining a healthy weight can help regulate menstruation and keep blood glucose levels under control. “A healthy, balanced diet and regular exercise are vital,” she tells.

Having PCOS does not mean you can’t get pregnant. PCOS is one of the most common but treatable causes of infertility in women. In women with PCOS, the hormonal imbalance interferes with the growth and release of eggs from ovaries (ovulation). So, the key to successful conception is to start treatment at the earliest,” Dr Jagtap advices. 

Dr Rajul Tyagi, Clinical Director – Javitri Hospital & Test Tube Baby Centre, Lucknow mentions that currently there is no cure for PCOS, but it can be well-managed. Treating PCOS will differ from person to person but mainly consists of ovarian stimulation drugs, insulin sensitising drugs or surgery. Most women with PCOS who are treated with a short course of drugs are able to get pregnant. There is no standard treatment plan that can work for every woman with PCOS who is planning a pregnancy.

“The fertility specialist will consider various factors before deciding on a treatment plan. These factors include age, symptoms, cause of infertility, personal desire to keep trying other routes of conception and last but not the least, cost of treatment. The doctors may prescribe different treatments like In Vitio Fertilisation (IVF) depending on the particular case. Speak to your doctor to understand if IVF is the best option for you,” Dr Tyagi advises. 

About Bharat Serums and Vaccines Ltd.

Bharat Serums and Vaccines Ltd. is one of the fastest growing bio-pharmaceutical companies in India. For over 50 years now, BSV has used its scientific resources to develop a range of biological, biotech and pharmaceutical products to treat various types of diseases, especially in the IVF, women’s health and critical care space and continues to contribute to preserve, protect and enhance the quality of life. BSV has been consistent in its efforts to raise public awareness on issues pertaining to women’s health and IVF.

To know more, visit www.bsvstartivf.com 

Disclaimer:

‘A public awareness initiative by Bharat Serums and Vaccines Limited, intended for general medical and health information and educational purposes only. Always seek the advice of your physician on any questions you may have regarding a medical condition or treatment before undertaking a new health care regimen’.

 Photo: https://oyefilmy.com/wp-content/uploads/2021/10/bsv-launches-pcos-awareness-drive-1.jpg

 

Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

Leave a Reply

News Wire

Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network

MUMBAI, India, March 11, 2026 /PRNewswire/ — Reliance Digital announces the offline retail availability of iQOO, the high-performance smartphone brand built for today’s youth and tech-forward consumers. Following strong traction in online channels, iQOO is now extending its presence into physical retail, allowing customers to experience and purchase its devices first-hand at Reliance Digital stores across India.

Known for pushing the boundaries of speed, and power, the iQOO 15R is powered by the Snapdragon 8 Gen 5, delivering exceptional speed, responsiveness, and sustained performance throughout the day. It packs iQOO’s biggest battery yet in an ultra-slim 7.90mm design, making it India’s slimmest smartphone with a 7600 mAh battery.

The device features a 6.5K IceCore VC Cooling Chamber for stable performance and runs on OriginOS 6.0 based on Android 16 out of the box, supported by 4 years of software updates and 6 years of security updates. It is also equipped with a Sony LYT-700V OIS camera, a 1.5K 144Hz AMOLED EyeCare display, and IP68 & IP69 dust and water resistance, making it a dependable daily partner for professionals on the go.

The brand’s offline expansion marks an important step in deepening consumer engagement by offering hands-on access to its devices, enabling customers to explore iQOO’s powerful performance, advanced display technology, and flagship-grade camera capabilities in a real-world retail environment.

The availability of iQOO at Reliance Digital brings together two brands driven by innovation and consumer experience. While iQOO continues to build its reputation as a performance-led smartphone brand, Reliance Digital strengthens its portfolio by offering customers access to cutting-edge technology brands through its extensive nationwide retail network.

Through engaging in-store experiences, knowledgeable staff, and immersive product demonstrations, Reliance Digital aims to help consumers better understand iQOO’s performance-first DNA. This move further reinforces Reliance Digital’s commitment to staying ahead of evolving consumer preferences and serving as a preferred destination for discovering new-age technology.

With this expansion, Reliance Digital continues to play a key role in shaping India’s consumer electronics landscape by bringing future-ready brands closer to customers, while enabling smartphone brands like iQOO to build stronger connections with a growing, performance-driven audience.

The all new iQOO 15R is now available at Reliance Digital stores nationwide.

Photo: https://oyefilmy.com/wp-content/uploads/2026/03/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-302711079.html

Continue Reading

News Wire

Kotak Alts announces winner of the inaugural Katalyst Awards

Ms Himani Choudhary named Katalyst for the year – India’s Best Financial Content Creator; wins Rs. 25 Lakhs

MUMBAI, India, March 10, 2026 /PRNewswire/ — Kotak Katalyst Awards, a national initiative instituted to recognise excellence and responsibility in financial content creation has announced the winner of its first Katalyst edition. Kotak Alternate Asset Managers Limited (“Kotak Alts”) today announced Himani Choudhary as the winner. The winner was awarded a prize of INR 25 Lakhs, positioning Katalyst among the most meaningful recognitions for financial content creators in India.

Srini Sriniwasan, Managing Director, Kotak Alts, said, “The Kotak Alts Katalyst Awards were instituted to recognize content creators who are contributing meaningfully to financial literacy in India. As investor participation deepens, audiences are seeking clarity, context, and credibility. The response from creators was overwhelming and points to the new generation of financial educators.  As the inaugural winner Ms. Himani Chaudhary, exemplifies the standard of financial communication that Katalyst seeks to encourage.”

The first edition of the Kotak Alts Katalyst Awards received over six hundred entries from across 19 states and in 8 languages, reflecting the growing role of digital creators in shaping financial awareness. Conceived in response to increasing clutter and misinformation in the financial ecosystem, Katalyst is designed to recognize creators who place accuracy, transparency, and investor interest at the core of their work.

The winning content, ‘Personal Finance & Major Finance Updates’ by Himani Choudhary, was recognised for its clarity, originality, and credibility. The jury noted the content’s ability to explain complex financial concepts in a clear and measured manner, supported by strong research and a consistent focus on investor education over virality.

To ensure a robust and transparent evaluation process, the awards framework was designed and audited by EY. The top thirty entries were assessed by an academic jury.

The top 10 finalists were subsequently evaluated by a grand jury comprising Kunal Shah, Founder and CEO of CRED; Radhika Gupta, Managing Director and CEO of Edelweiss Mutual Fund; and Alpesh Shah, Managing Director and Senior Partner at Boston Consulting Group, and chaired by Ananth Narayan, former Whole–Time Member of SEBI with extensive capital markets and regulatory experience.

The Katalyst Awards recognise financial content creators who priorities financial literacy, substance, and long–term investor interest. Through this initiative, Kotak Alts aims to encourage responsible financial communication and support the development of informed and confident investors across India.

About Kotak Alternate Asset Managers Ltd: Kotak Alternate Asset Managers Limited (‘Kotak Alts’), a part of Kotak Mahindra Group (‘Kotak’), focuses on Alternate Asset Management and Investment Advisory businesses. Kotak Alts was set up in early 2005 and has raised, managed, and advised over USD 22 billion across different asset classes, including Private Equity, Real Estate, Infrastructure, Special Situations, Private Credit, and Investment Advisory. The asset management business and investment advisory vertical are managed by independent specialist teams. For more information, visit https://www.kotakalternateasset.com/

Image: https://oyefilmy.com/wp-content/uploads/2026/03/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-1.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-302709187.html

Continue Reading

News Wire

Paperpal for Life Sciences Establishes HIPAA Readiness, Strengthening Enterprise Adoption of AI in Regulated Medical and Scientific Writing Workflows

MUMBAI, India, March 10, 2026 /PRNewswire/ — Paperpal for Life Sciences, an enterprise-grade Artificial Intelligence (AI) platform by Cactus Communications, purpose-built for Medical Affairs and Life Sciences organizations, announced the completion of an assessment evaluating its operational and technical safeguards to support Health Insurance Portability and Accountability Act (HIPAA) requirements. This milestone reinforces Paperpal’s commitment to meeting the rigorous standards of security, data protection, and regulatory readiness required for regulated scientific workflows.

Growing AI use in medical affairs writing and publication workflows is intensifying scrutiny on data privacy, governance, and regulatory accountability. To support these evolving needs, Paperpal for Life Sciences has undertaken an assessment of its systems and processes to evaluate readiness to support HIPAA compliance, where applicable, and now proudly offers the option to execute a Business Associate Agreement (BAA) for Protected Health Information (PHI) and Personally Identifiable Information (PII). This offering gives customers the confidence that PHI or PII, if received, is handled securely and responsibly, in line with regulatory expectations and enterprise risk management practices.

Paperpal for Life Sciences provides AI writing, literature search, source-grounded summarization with citation support, and critical publication checks, powering medical affairs content creation under stringent data privacy and governance controls. The platform accelerates research-to-publication timelines by upto 25%, supporting faster dissemination of clinical evidence and earlier commercialization of new drugs and therapies.

Nishchay Shah, Group CTO and EVP, Products and AI at Cactus Communications, said, “As AI becomes foundational to regulated scientific and medical workflows, compliance and trust are no longer optional. Paperpal for Life Sciences’ HIPAA readiness measures reflect our secure-by-design approach to AI, strong data governance framework, and alignment with real-world enterprise and regulatory requirements. This milestone enables organizations to adopt AI at scale with confidence that their data, processes, and compliance obligations are protected .”

Elvira Dsouza, President, Cactus Life Sciences, added, “Medical Affairs and Life Sciences teams operate in highly regulated environments where scientific rigor, data privacy, and compliance are non-negotiable. HIPAA readiness positions Paperpal for Life Sciences as a trusted AI partner, one that enables organizations to accelerate evidence generation and scientific communication without compromising regulatory integrity .”

With this announcement, Paperpal for Life Sciences reinforces its position as a purpose-built, enterprise-ready AI platform for medical affairs content generation that supports innovation while meeting the highest standards of privacy, ethics, and regulatory compliance.

Media Contact:

Nidhi Amin

nidhi.amin@cactusglobal.com 

Logo: https://oyefilmy.com/wp-content/uploads/2026/03/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-302708082.html

Continue Reading

Trending